文献速递类风湿关节炎

JAK抑制剂治疗失败后:换用另一种JAK抑制剂还是转换为生物制剂——来自JAK-pot注册登记协作的数据

After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
PubMed 文献 · Ann Rheum Dis · 2022-09-13

在17个国家注册登记组成的JAK-pot国际协作中,比较类风湿关节炎患者首个JAK抑制剂(JAKi)治疗失败后换用第二种JAKi(循环)与改用bDMARD的有效性。365例循环与1635例转换患者中,两种策略2年观察留存率相似,但校正分析显示循环与更高留存相关(p=0.04);CDAI改善相似。若首个JAKi因不良事件(AE)停用,第二种JAKi因AE停用的可能性更高。

要点

  • 首个JAKi失败后,换用JAKi与改用bDMARD的2年观察留存率相似。
  • 校正混杂后,循环JAKi与更高留存相关(p=0.04)。
  • 若首个JAKi因不良事件停用,第二种JAKi因不良事件停用的可能性更高。

核心结论

  • 首个JAKi治疗失败后,换用JAKi与改用bDMARD似乎具有相似的有效性。
  • 若停用首个JAKi的原因是AE,应谨慎。

研究设计与样本

  • 研究为JAK-pot协作(17个国家注册登记汇总数据)内的巢式队列研究。
  • 纳入类风湿关节炎患者,首个JAKi治疗失败后接受第二种JAKi或bDMARD治疗,前瞻性收集数据。
  • 采用log-rank检验和校正潜在混杂因素的Cox回归分析比较第二次治疗启动后的药物留存率差异。
  • 采用线性回归模型校正混杂因素估计CDAI随时间的变化。

主要发现

  • 共研究365例循环患者和1635例转换患者。
  • 循环者年龄更大,既往bDMARD数量更多。
  • 两种策略2年随访的观察留存率相似。
  • 校正分析显示循环与更高留存相关(p=0.04)。
  • 在循环者中,若首个JAKi因AE停用,第二种JAKi也更可能因AE停用。

关键数值与推荐

  • 循环组365例,转换组1635例。
  • 校正分析显示循环与更高留存相关,p=0.04。

临床怎么用

  • 首个JAKi失败后,换用JAKi与改用bDMARD似乎具有相似的有效性。
  • 若停用首个JAKi的原因是AE,应谨慎。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The expanded therapeutic arsenal in rheumatoid arthritis (RA) raises new clinical questions. The objective of this study is to compare the effectiveness of cycling Janus kinase inhibitors (JAKi) with switching to biologic disease-modifying antirheumatic drug (bDMARD) in patients with RA after failure to the first JAKi. METHODS: This is a nested cohort study within data pooled from an international collaboration of 17 national registries (JAK-pot collaboration). Data from patients with RA with JAKi treatment failure and who were subsequently treated with either a second JAKi or with a bDMARD were prospectively collected. Differences in drug retention rates after second treatment initiation were assessed by log-rank test and Cox regression analysis adjusting for potential confounders. Change in Clinical Disease Activity Index (CDAI) over time was estimated using a linear regression model, adjusting for confounders. RESULTS: 365 cycling and 1635 switching patients were studied. Cyclers were older and received a higher number of previous bDMARDs. Both strategies showed similar observed retention rates after 2 years of follow-up. However, adjusted analysis revealed that cycling was associated with higher retention (p=0.04). Among cyclers, when the first JAKi was discontinued due to an adverse event (AE), it was more likely that the second JAKi would also be stopped due to an AE. Improvement in CDAI over time was similar in both strategies. CONCLUSIONS: After failing the first JAKi, cycling JAKi and switching to a bDMARD appear to have similar effectiveness. Caution is advised if an AE was the reason to stop the first JAKi.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Pombo-Suarez M, Sanchez-Piedra C, Gómez-Reino J, et al. After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries. Ann Rheum Dis. 2022. PMID: 36100351. doi:10.1136/ard-2022-222835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。